Literature DB >> 3546145

The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.

R Vanhoof, J M Hubrechts, E Roebben, H J Nyssen, E Nulens, J Leger, N De Schepper.   

Abstract

In this study, we compared the activity of pefloxacin, enoxacin and ciprofloxacin against 269 enteropathogenic strains (Campylobacter jejuni, enteropathogenic Escherichia coli, Salmonella typhi, Shigella spp., Vibrio cholerae and Yersinia enterocolitica) with that of rosoxacin, flumequin, nifuroxazide, erythromycin, chloramphenicol, ampicillin, cefotaxime, tetracycline, amikacin, netilmicin, sulfamethoxazole, trimethoprim and co-trimoxazole. Pefloxacin, enoxacin and ciprofloxacin were always among the most active compounds. Furthermore, resistant strains or strains with elevated MIC values were not found. The MIC90 value for these three compounds was less than or equal to 0.25 mg/l, except for C. jejuni where it was 0.3 mg/l and 1.4 mg/l for pefloxacin and enoxacin, respectively.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3546145     DOI: 10.1007/BF01643966

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  Antimicrobial susceptibility of Vibrio cholerae from Zaire and Rwanda.

Authors:  J Colaert; E van Dyck; J P Ursi; P Piot
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Nalidixic-acid-resistant Shigella dysenteriae I.

Authors:  B R Panhotra; B Desai; P L Sharma
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

5.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

Authors:  R Vanhoof; M P Vanderlinden; R Dierickx; S Lauwers; E Yourassowsky; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

6.  Yersinia enterocolitica: in vitro antimicrobial susceptibility.

Authors:  M Raevuori; S M Harvey; M J Pickett; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

7.  In-vitro susceptibility of salmonellae to antimicrobial agents.

Authors:  H Goossens; R Vanhoof; P De Mol; O Grados; G Ghysels; J P Butzler
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

8.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

9.  In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics.

Authors:  M J Hornstein; A M Jupeau; M R Scavizzi; A M Philippon; P A Grimont
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

10.  Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni.

Authors:  R Vanhoof; B Gordts; R Dierickx; H Coignau; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  13 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults.

Authors:  E Gotuzzo; R A Oberhelman; C Maguiña; S J Berry; A Yi; M Guzman; R Ruiz; R Leon-Barua; R B Sack
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  Epidemiological, clinical and therapeutic evaluation of the Italian cholera epidemic in 1994.

Authors:  P Maggi; S Carbonara; C Fico; T Santantonio; C Romanelli; E Sforza; G Pastore
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

Review 4.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Monitoring of antibiotic resistance in shigellae isolated in The Netherlands 1984-1989.

Authors:  C E Voogd; C S Schot; W J van Leeuwen; B van Klingeren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

7.  In vitro activity of eight antibiotics against Salmonella and Shigella species.

Authors:  D Arman; A Willke; D Tural
Journal:  Eur J Epidemiol       Date:  1994-06       Impact factor: 8.082

Review 8.  Use of quinolones in the treatment of gastrointestinal infections.

Authors:  H L DuPont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Comparative in vitro activity of ceftibuten (Sch 39720) against bacterial enteropathogens.

Authors:  R Shawar; M LaRocco; T G Cleary
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.